Regencell Bioscience Holdings Limited

NasdaqCM:RGC Stock Report

Market Cap: US$76.4m

Regencell Bioscience Holdings Valuation

Is RGC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of RGC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate RGC's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate RGC's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for RGC?

Key metric: As RGC is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for RGC. This is calculated by dividing RGC's market cap by their current book value.
What is RGC's PB Ratio?
PB Ratio9.3x
BookUS$8.22m
Market CapUS$76.39m

Price to Book Ratio vs Peers

How does RGC's PB Ratio compare to its peers?

The above table shows the PB ratio for RGC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average1.9x
LABP Landos Biopharma
3.1x-37.1%US$71.7m
ZYNE Zynerba Pharmaceuticals
2.3x67.2%US$65.6m
RLMD Relmada Therapeutics
1.7x-11.2%US$84.5m
IKNA Ikena Oncology
0.6x4.6%US$82.5m
RGC Regencell Bioscience Holdings
9.3xn/aUS$76.4m

Price-To-Book vs Peers: RGC is expensive based on its Price-To-Book Ratio (9.3x) compared to the peer average (1.8x).

Price to Book Ratio vs Industry

How does RGC's PB Ratio compare vs other companies in the US Pharmaceuticals Industry?

23 CompaniesPrice / BookEstimated GrowthMarket Cap
SHWZ Medicine Man Technologies
0.09xn/aUS$8.82m
TNFA TNF Pharmaceuticals
0.2xn/aUS$3.69m
UPC Universe Pharmaceuticals
0.1xn/aUS$3.04m
CYTO Altamira Therapeutics
0.2x-5.9%US$1.44m
RGC 9.3xIndustry Avg. 1.7xNo. of Companies28PB01.22.43.64.86+
23 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: RGC is expensive based on its Price-To-Book Ratio (9.3x) compared to the US Pharmaceuticals industry average (1.8x).

Price to Book Ratio vs Fair Ratio

What is RGC's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RGC PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio9.3x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate RGC's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Spectrum Pharmaceuticals

US$209.9m

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products.

SPPI

US$1.03

7D

5.3%

1Y

17.0%

IQVIA Holdings

US$36.6b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$204.02

7D

6.8%

1Y

-3.2%

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$58.64

7D

6.1%

1Y

14.8%